PX1 Research has expanded its peptide catalog with new batches of Retatrutide and Tirzepatide research peptides, both manufactured in USA cGMP-certified facilities and verified through rigorous HPLC batch verification. The company reports that every batch achieves purity ratings of 99% or above, supported by Certificates of Analysis available for each product.
The release underscores the importance of manufacturing standards in peptide research. cGMP compliance governs facility conditions, equipment qualification, personnel training, and documentation practices, providing a traceable chain of production for research institutions. With over 16 years of peptide manufacturing expertise, PX1 Research emphasizes that domestic production under these standards can materially affect data integrity in experiments requiring consistent compound performance.
Each batch undergoes a seven-stage testing protocol prior to shipment, with HPLC batch verification as the analytical backbone. This method separates peptide compounds to quantify purity with high resolution, while additional checkpoints detect endotoxin contamination, verify amino acid sequence integrity, and confirm accurate mass through spectrometric analysis. The result is a batch-specific Certificate of Analysis, ensuring that every shipment carries documentation reflecting its own test results rather than generalized lot data.
Both peptides hold significant positions in metabolic and endocrine research. Tirzepatide functions as a dual GIP and GLP-1 receptor agonist, while Retatrutide extends this mechanism as a triple agonist by also engaging the glucagon receptor. The structural complexity of these molecules demands manufacturing precision, as minor sequence deviations can alter receptor binding profiles. By offering both peptides under the same cGMP and verification framework, PX1 Research enables research teams to compare the two molecules or run parallel study arms with comparable documentation standards.
The newly released batches are available through PX1 Research's catalog, with Retatrutide accessible at px1research.com and Tirzepatide also at px1research.com. Certificates of Analysis for current batch numbers are provided alongside each product listing.
This release highlights the importance of sourcing high-purity peptides with transparent quality assurance, especially in fields where reproducibility is critical. By prioritizing cGMP manufacturing and batch-level verification, PX1 Research aims to support the integrity of research outcomes.
